It compared the financial impact of TearCare to commonly prescribed dry eye medications, including Restasis 0.05% branded and generic, and Xiidra 5%. Key findings indicated that a 20% increase in ...

Third-quarter revenues for 2024 saw a substantial 19% year-over-year increase, reaching $1.196 billion. This growth was primarily driven by products such as Miebo and Xiidra, and the contact lens ...

Additionally, the company's products in the dry eye category, Miebo and Xiidra, are anticipated to contribute to growth in the coming year, although there are concerns regarding the impact of the ...

The company reported a substantial 19% year-over-year increase in third quarter revenues for 2024, reaching $1.196 billion. This growth was primarily driven by products such as Miebo and Xiidra, and ...